CL2016001097A1 - Inhibidor de beta-lactamasa cristalina - Google Patents

Inhibidor de beta-lactamasa cristalina

Info

Publication number
CL2016001097A1
CL2016001097A1 CL2016001097A CL2016001097A CL2016001097A1 CL 2016001097 A1 CL2016001097 A1 CL 2016001097A1 CL 2016001097 A CL2016001097 A CL 2016001097A CL 2016001097 A CL2016001097 A CL 2016001097A CL 2016001097 A1 CL2016001097 A1 CL 2016001097A1
Authority
CL
Chile
Prior art keywords
lactamase inhibitor
methyl
crystalline beta
beta
lactamase
Prior art date
Application number
CL2016001097A
Other languages
English (en)
Spanish (es)
Inventor
Alessandro Lamonica
Marco Forzatti
Stefano Biondi
Original Assignee
Allecra Therapeutics Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49818360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001097(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allecra Therapeutics Sas filed Critical Allecra Therapeutics Sas
Publication of CL2016001097A1 publication Critical patent/CL2016001097A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/86—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/87—Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2016001097A 2013-11-08 2016-05-06 Inhibidor de beta-lactamasa cristalina CL2016001097A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1319776.9A GB201319776D0 (en) 2013-11-08 2013-11-08 Compound
GBGB1408643.3A GB201408643D0 (en) 2013-11-08 2014-05-15 Compound

Publications (1)

Publication Number Publication Date
CL2016001097A1 true CL2016001097A1 (es) 2016-12-02

Family

ID=49818360

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001097A CL2016001097A1 (es) 2013-11-08 2016-05-06 Inhibidor de beta-lactamasa cristalina

Country Status (14)

Country Link
US (2) US20160289245A1 (cg-RX-API-DMAC7.html)
EP (1) EP3066103A1 (cg-RX-API-DMAC7.html)
JP (2) JP7045795B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160081964A (cg-RX-API-DMAC7.html)
CN (1) CN105873935B (cg-RX-API-DMAC7.html)
AU (1) AU2014345507B2 (cg-RX-API-DMAC7.html)
CA (1) CA2929199C (cg-RX-API-DMAC7.html)
CL (1) CL2016001097A1 (cg-RX-API-DMAC7.html)
EA (1) EA031348B1 (cg-RX-API-DMAC7.html)
GB (2) GB201319776D0 (cg-RX-API-DMAC7.html)
IL (1) IL245386A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016005869A (cg-RX-API-DMAC7.html)
PE (1) PE20160890A1 (cg-RX-API-DMAC7.html)
WO (1) WO2015067787A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319776D0 (en) * 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
WO2026086730A1 (zh) * 2024-10-21 2026-04-30 齐鲁制药有限公司 恩美他唑巴坦的晶型及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
ATE219085T1 (de) * 1997-12-29 2002-06-15 Res Corp Technologies Inc 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren
US7273935B2 (en) * 2003-08-21 2007-09-25 Orchid Chemicals & Pharmaceuticals, Ltd. Process for the preparation of 3-methylcepham derivatives
US7417143B2 (en) * 2004-04-07 2008-08-26 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of Tazobactam in pure form
WO2008010048A2 (en) * 2006-07-12 2008-01-24 Orchid Chemicals & Pharmaceuticals Limited Novel 2-substituted methyl penam derivatives
EA030662B1 (ru) * 2010-11-25 2018-09-28 Аллекра Терапойтикс Гмбх β-ЛАКТАМОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-ЛАКТАМАЗЫ И ИХ ПРИМЕНЕНИЕ
US20150140059A1 (en) * 2012-05-07 2015-05-21 The Regents Of The University Of California Novel oxysterol analogue, oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis
JP2016517888A (ja) * 2013-05-02 2016-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 骨選択的骨形成のオキシステロール骨標的薬剤
GB201319776D0 (en) 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
GB201408649D0 (en) * 2014-05-15 2014-07-02 Allecra Therapeutics Sas Method
US9657052B2 (en) * 2014-12-09 2017-05-23 Warsaw Orthopedic, Inc. Compounds and methods of making sterols using diols

Also Published As

Publication number Publication date
CA2929199A1 (en) 2015-05-14
AU2014345507A1 (en) 2016-05-19
MX2016005869A (es) 2017-01-05
AU2014345507B2 (en) 2018-11-22
JP2016535054A (ja) 2016-11-10
CN105873935B (zh) 2019-03-19
US20190071456A1 (en) 2019-03-07
PE20160890A1 (es) 2016-08-25
JP7346485B2 (ja) 2023-09-19
EP3066103A1 (en) 2016-09-14
JP7045795B2 (ja) 2022-04-01
EA201690963A1 (ru) 2016-10-31
CN105873935A (zh) 2016-08-17
EA031348B1 (ru) 2018-12-28
GB201408643D0 (en) 2014-07-02
WO2015067787A1 (en) 2015-05-14
JP2021102642A (ja) 2021-07-15
US11124526B2 (en) 2021-09-21
GB201319776D0 (en) 2013-12-25
US20160289245A1 (en) 2016-10-06
KR20160081964A (ko) 2016-07-08
CA2929199C (en) 2023-01-03
IL245386A0 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
CL2014003035A1 (es) Compuestos derivados de diazabiciclooctano, inhibidores de beta-lactamasa; composicion farmaceutica que los comprende; proceso para prepararlos; y metodo para tratar una infeccion bacteriana.
CL2015001667A1 (es) Derivados de manosa para tratar infecciones bacterianas.
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
EA201401292A3 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
EA201400753A1 (ru) Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
BR112014003587A8 (pt) Derivados de 5-flúor-4-imino-3-(substituído)-3,4-dihidropirimidin-2(1h)ona, composição e método para controle ou prevenção de um patógeno fúngico
GT201300213A (es) Derivados de fluoro-piridinona útiles como agentes antibacterianos
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
DOP2014000212A (es) Compuestos inhibidores de beta-lactamasas
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
EA201591527A1 (ru) Новые производные пиридина
AU2012321815A8 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
CL2018000688A1 (es) Compuestos heterociclicos que contienen bencilamina y composiciones útiles contra infección por micobacterias
EA201600121A1 (ru) Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
EA201790496A1 (ru) Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm
EA201500931A1 (ru) Производные пиридин-4-ила
MX375438B (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
AU2016248387A8 (en) Preparation and use of kinase inhibitor